JOINT FILING AGREEMENT
EXHIBIT 1
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13G (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of December 31, 2006.
|
|
|
/s/ Xxxx Xxxxx |
|||||||
|
|
Xxxx Xxxxx |
||||||||
|
|
|
|
|||||||
|
|
|
|
|||||||
|
|
|
/s/ Xxx Xxxx Xxxxxx |
|||||||
|
|
Xxx Xxxx Xxxxxx |
||||||||
|
|
|
|
|||||||
|
|
|
|
|||||||
|
|
Efficacy Capital Ltd., |
||||||||
|
|
a Bermuda limited liability company |
||||||||
|
|
|
|
|||||||
|
|
|
/s/ Xxxx Xxxxx |
|||||||
|
|
By: |
Xxxx Xxxxx |
|||||||
|
|
Its: |
Managing Partner |
|||||||
|
|
|
|
|||||||
|
|
Efficacy Biotech Fund, L.P., |
||||||||
|
|
a Delaware limited partnership |
||||||||
|
|
|
|
|||||||
|
|
|
By: |
Efficacy Capital Ltd. |
|
|||||
|
|
|
Its: |
General Partner |
|
|||||
|
|
|
|
|||||||
|
|
|
|
/s/ Xxxx Xxxxx |
||||||
|
|
|
By: |
Xxxx Xxxxx |
||||||
|
|
|
Its: |
Managing Partner |
||||||
|
|
|
|
|||||||
|
|
Efficacy Biotech Fund Limited, |
||||||||
|
|
a Bermuda Exempted Mutual Fund Company |
||||||||
|
|
|
|
|||||||
|
|
|
By: |
Efficacy Capital Ltd. |
|
|||||
|
|
|
Its: |
Manager |
|
|||||
|
|
|
|
|||||||
|
|
|
|
/s/ Xxxx Xxxxx |
||||||
|
|
|
By: |
Xxxx Xxxxx |
|
|||||
|
|
|
Its: |
Managing Partner |
|
|||||
|
|
|
|
|||||||
|
|
Efficacy Biotech Master Fund Ltd., |
||||||||
|
|
a Bermuda Exempted Mutual Fund Company |
||||||||
|
|
|
|
|||||||
|
|
|
By: |
Efficacy Capital Ltd. |
|
|||||
|
|
|
Its: |
Manager |
|
|||||
|
|
|
|
|||||||
|
|
|
|
/s/ Xxxx Xxxxx |
||||||
|
|
|
By: |
Xxxx Xxxxx |
|
|||||
|
|
|
Its: |
Managing Partner |
|
|||||
1
